Reference entry · Tuftsin-derived heptapeptide
Selank
Also known as: Tuftsin analog · TPR-Glu-Trp-Pro-Arg-Pro-Gly-Pro
- Class
- Tuftsin-derived heptapeptide
- Size
- 7 amino acids
- Primary targets (literature)
- GABAergic modulation (literature); immunomodulatory pathways
- Regulatory context
- Registered as a drug in Russia for defined indications; not FDA-approved. Catalog Selank requires batch identity confirmation.
Overview
Selank is a synthetic heptapeptide derived from tuftsin with an added Gly-Pro C-terminal extension. Russian and Western literature describes anxiolytic-like effects in rodent models without classical benzodiazepine sedation, plus immunomodulatory research angles.
Mechanism in research literature
Proposed GABAergic modulation, enkephalinase inhibition, and cytokine-related immunomodulation in preclinical literature — mechanistic consensus across independent labs remains limited.
Common research focus areas
- Rodent anxiety and stress models
- Immunomodulatory and cytokine endpoints
- Comparison with tuftsin parent sequence
- Modified amidate analog identity verification
Full literature roundup
Read the cited research summary
A tuftsin-derived heptapeptide studied in anxiolytic and immunomodulatory models. Russian pharmacology context, literature scope, and material quality.
Selank research roundup · 6 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.